NIDDK Office of Technology Transfer and Development

Cold Spring Harbor Laboratory and Deerfield Management Launch Harbor Discoveries to Advance New Therapeutics

Retrieved on: 
Thursday, January 5, 2023
Transfer, Medical research, Partner (business rank), Biotechnology, Research, CSHL, NIDDK Office of Technology Transfer and Development, Patient, Cold Spring Harbor Laboratory, Business development, Therapy, Biomedicine, Technology transfer, Biomedical Research, Pharmaceutical industry

NEW YORK, Jan. 5, 2023 /PRNewswire/ -- Cold Spring Harbor Laboratory (CSHL) and healthcare investment firm, Deerfield Management, today announced a research and development collaboration to help bring next-generation therapeutics to market. Through a newly launched company called Harbor Discoveries, LLC, Deerfield has committed up to $130 million over a 10-year period and will provide CSHL scientists with both funding and functional expertise to advance biomedical research.

Key Points: 
  • NEW YORK, Jan. 5, 2023 /PRNewswire/ -- Cold Spring Harbor Laboratory (CSHL) and healthcare investment firm, Deerfield Management, today announced a research and development collaboration to help bring next-generation therapeutics to market.
  • Through a newly launched company called Harbor Discoveries, LLC, Deerfield has committed up to $130 million over a 10-year period and will provide CSHL scientists with both funding and functional expertise to advance biomedical research.
  • Harbor Discoveries, LLC is a private company wholly owned by affiliates of Deerfield Management.
  • In exchange for these resources, Harbor Discoveries, LLC will have the option to license the associated intellectual property and know-how developed at CSHL.

Accomplished Physicist Duncan Brown Appointed Syracuse University’s Next Vice President for Research

Retrieved on: 
Friday, June 10, 2022
Transfer, Undergraduate research, Science, California Institute of Technology, Faculty, Director, Leadership, Social, Veteran, Biology, COVID, Cornell University Board of Trustees, Technology transfer, Biotechnology, S-1 Executive Committee, Knowledge, Laser, National Science Board, American Physical Society, NIDDK Office of Technology Transfer and Development, Policy, Material, Executive Committee, Creativity, Humanities, University, American, Provost, Student, GLOBE, Publication, Disability studies, Carnegie, National Science Foundation, LIGO, Board, Engineering, Milwaukee, United States Office of Research Integrity, Education, Syracuse University, Technology, Management, Medicine, Physics, Astronomy, Trustee, Research

Syracuse, June 10, 2022 (GLOBE NEWSWIRE) -- Gretchen Ritter, vice chancellor, provost and chief academic officer, today announced Duncan Brown, the Charles Brightman Endowed Professor of Physics and an accomplished physicist, has been appointed Syracuse Universitys next vice president for research.

Key Points: 
  • Syracuse, June 10, 2022 (GLOBE NEWSWIRE) -- Gretchen Ritter, vice chancellor, provost and chief academic officer, today announced Duncan Brown, the Charles Brightman Endowed Professor of Physics and an accomplished physicist, has been appointed Syracuse Universitys next vice president for research.
  • Duncan is uniquely suited to support Syracuse Universitys faculty scholars in their efforts to pursue and secure external funding that advances their research, scholarship and creative work.
  • The role of the vice president for research is to advance all areas of the Universitys research, scholarship and creative work, says Brown.
  • In fact, he was the chair of the search committee appointed to find the next vice president of research.

University of Maryland, Baltimore (UMB) Grants GlycoMantra Exclusive License to Advance the Company's Therapeutic Pipeline

Retrieved on: 
Monday, March 7, 2022
Transfer, Apoptosis, Toxicity, Dentistry, Fibrosis, Patient, MBA, Death, Research, Woman, Carbohydrate, History of the University of Maryland, College Park, Society, Biotechnology, Doctor of Philosophy, CRC, Technology, University, Cell death, Technology transfer, Colorectal cancer, Survival, Cancer, Man, DO, Pharmacy, Lists of diseases, NASH, Prostate cancer, Medicine, CSCS, Maryland School, CEO, Neoplasm, Cell, Venture, University of Maryland, College Park, UMB, Type 2 diabetes, Protein, NIDDK Office of Technology Transfer and Development, Diabetes, Nursing, Drug resistance, Social work, Therapy, Pharmaceutical industry, Pediatrics

Although 5-fluorouracil (5-FU)one of the current standards of care for patients with mCRCexerts clinical benefit, all patients have acquired resistance to the drug over time.

Key Points: 
  • Although 5-fluorouracil (5-FU)one of the current standards of care for patients with mCRCexerts clinical benefit, all patients have acquired resistance to the drug over time.
  • Aditi Banerjee, PhD, of the University of Maryland School of Medicine Department of Pediatrics, is the lead inventor of the technology.
  • "The combination therapy we're pursuing is anticipated to be a significant advancement in the arsenal against mCRC.
  • "This licensing agreement with the University of Maryland, Baltimore will allow us to advance our very important research and development."

CoapTech Awarded Seed Fund Grant from Pennsylvania Pediatric Device Consortium

Retrieved on: 
Thursday, January 27, 2022
Transfer, Magnet, University, View, Risk, PUMA, University of Maryland, College Park, Regulation of tobacco by the U.S. Food and Drug Administration, Radiation, Children's Hospital of Philadelphia, Patient, Philadelphia, UMB, Technology, Associate, FDA, Twitter, Multimedia, Einstein Medical Center Philadelphia, Cancer, End organ damage, Adult, Health, Hospital, Technology transfer, CHOP, History of the University of Maryland, College Park, Food, Drexel University, Children's Hospital, Solution, NIDDK Office of Technology Transfer and Development, Dentistry, Medicine, Child

BALTIMORE, Jan. 27, 2022 /PRNewswire/ -- CoapTech, Inc,a medical device company focused ondelivering transformative solutions for minimally-invasive surgery, announced today it has been awarded a $50,000 grant by the Children's Hospital of Philadelphia-based Pennsylvania Pediatric Medical Device Consortium ("PPDC") for its PUMA-G Peds System, a device designed to provide a safer way to place feeding tubes in children.

Key Points: 
  • BALTIMORE, Jan. 27, 2022 /PRNewswire/ -- CoapTech, Inc,a medical device company focused ondelivering transformative solutions for minimally-invasive surgery, announced today it has been awarded a $50,000 grant by the Children's Hospital of Philadelphia-based Pennsylvania Pediatric Medical Device Consortium ("PPDC") for its PUMA-G Peds System, a device designed to provide a safer way to place feeding tubes in children.
  • It is designed to operate like the currently available adult PUMA-G System, with modifications to accommodate the pediatric patient population.
  • "CoapTech is honored to receive this competitive award from PPDC," said CoapTech Co-founder and CEO Howard Carolan.
  • "The consortium chose CoapTech as one of five awardees from ten finalists in competition to receive grants.

University of Maryland, Baltimore (UMB) Grants Pumas-AI Exclusive License of Analytics Platform to Enhance Drug Development

Retrieved on: 
Monday, August 16, 2021
Transfer, Center, MBA, Social work, UMB, Dentistry, Maryland School, DO, Venture, Live Nation Entertainment, University, Science, Medicine, School, Technology, Doctor of Philosophy, FDA, Biotechnology, Investment, Growth, Productivity, Nursing, History of the University of Maryland, College Park, Translational medicine, Workflow, USC School of Pharmacy, Technology transfer, NIDDK Office of Technology Transfer and Development, Medical device, Management

BALTIMORE, Aug. 16, 2021 /PRNewswire/ --Pumas-AI, aUniversity ofMaryland,Baltimore(UMB)startup company, has been granted worldwide, exclusive rights to enhancements to Pumas, an end-to-end pharmaceutical modeling and simulation platform for quantitative analysis across the drug development lifecycle.

Key Points: 
  • BALTIMORE, Aug. 16, 2021 /PRNewswire/ --Pumas-AI, aUniversity ofMaryland,Baltimore(UMB)startup company, has been granted worldwide, exclusive rights to enhancements to Pumas, an end-to-end pharmaceutical modeling and simulation platform for quantitative analysis across the drug development lifecycle.
  • Pumas 2.0 builds on the company's existing platform, which also employs technology licensed from UMB.
  • Pumas provides pharmaceutical and biotechnology companies and their investors usable quantitative metrics on technical, regulatory, and commercial success probabilities.
  • Users can quickly translate predictive insight into real-world decisions, and explore a wide range of questions for more valuable insights while effectively de-risking investments.